News | November 05, 2021
UK authorises first Covid-19 pill
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The company plans to expand its portfolio in regulated markets aggressively
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
Subscribe To Our Newsletter & Stay Updated
